A Dual MYC and GSPT1 Degrader Extended Survival by Over 300% in One Preclinical Model
The loop is the discovery, not the degrader. If GSPT1 supports MYC translation, a GSPT1-only degrader should permit MYC to recover.
venetoclax
NICE Backed Acalabrutinib and Venetoclax Without Obinutuzumab, and the Omission Is the Decision
AMPLIFY tested acalabrutinib and venetoclax with and without obinutuzumab. NICE recommended the doublet, which is a decision about infusions.